Age-related macular degeneration occurs much earlier than previously assumed

July 21, 2014

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries. However, it is questionable whether it can continue to be defined as a disease in people in their 50s and beyond. Investigations to determine the incidence of age-related macular degeneration undertaken as part of the Gutenberg Health Study of the University Medical Center of Johannes Gutenberg University Mainz (JGU) have shown that even persons under the age of 50 years may be affected by an early form of the eye disease. Just under 4 percent of the 35 to 44-year-old subjects in the population-based study were found to be suffering from AMD.

In order to identify the age- and gender-specific incidence of AMD, the research team of the Department of Ophthalmology at the Mainz University Medical Center led by Dr. Christina Korb, PD Dr. Alireza Mirshahi, and Professor Norbert Pfeiffer assessed the status of the ocular fundus of 4,340 participants in the Gutenberg Health Study. Evaluated were vascular structure, the head of the optic nerve, and the macula of the eye, which is the point of sharpest vision. The results in general documented that the incidence of AMD increases with age. However, the researchers also discovered to their surprise that even persons under the age of 50 years can already be affected by early stage AMD. In the age group of 35- to 44-year-olds, 3.8 percent of the subjects in the Gutenberg Health Study were found to be suffering from the disease. The findings of the Mainz researchers thus contradict the current assumption that only occurs in the section of the population that is over 50 years old.

With the help of their findings, the researchers were also able to gain insights into how frequently the various forms of age-related occur. On average, about 12 percent of the examined 35- to 74-year-olds had early stage AMD, but only 0.2 percent of the study participants exhibited symptoms of late stage AMD, which is often associated with severe . "Our research shows that age-related macular degeneration can already occur much earlier than previously thought. This means there may also be possible consequences with regard to the screening examinations for these diseases," concluded Dr. Christina Korb.

Age-related macular degeneration leads to loss of visual acuity. The cause is damage to the cells in the region of the central retina also known as the "yellow spot." There is still insufficient information on the annual number of individuals who develop AMD and the Mainz-based researchers hope to be able to remedy this with the help of their next project. As the Gutenberg cohort was subjected to a follow-up examination five years after inclusion in the study, the research group has now access to more relevant and reliable data. "The prospective design of the study, in combination with the availability of interdisciplinary research data, should make it possible for us to identify risk factors for the development of late forms of AMD in our cohort. We are looking forward with some excitement to the results," explained the team. The objective is to reveal, for the first time, the incidence of AMD across the whole population of Germany.

The Gutenberg Health Study (GHS) is an interdisciplinary, population-based, prospective, monocenter cohort study, which has been conducted at the Mainz University Medical Center since 2007. Cardiovascular diseases, cancer, eye diseases, metabolic disorders as well as immune system and mental disorders are being investigated as part of the study. The goal of the study is to improve the individual risk prediction for these diseases. To this end, lifestyle, psychosocial factors, environment, clinical laboratory parameters, and the severity of any subclinical disorder are being taken into consideration. A comprehensive biorepository is being developed so that molecular biological investigations can be conducted. During the baseline visit, 15,010 participants aged 35 to 74 years were invited to participate in a 5-hour examination program at the study center. This was followed by a computer-assisted telephone interview (CATI) using a standardized questionnaire and the assessment of diseases and health problems after 2.5 years. All endpoints will be subjected to extensive validation. In April 2012, a detailed follow-up examination of participants similar to the baseline examination was conducted at the center five years after their inclusion in the study. The aim is to continue to monitor the cohort and conduct further tests.

Explore further: Some high blood pressure drugs may be associated with increased risk of vision-threatening disease

More information: C. A. Korb et al. (2014), "Prevalence of age-related macular degeneration in a large European cohort: Results from the population-based Gutenberg Health Study," Graefe's Archive for Clinical and Experimental Ophthalmology, DOI: 10.1007/s00417-014-2591-9

Related Stories

Some high blood pressure drugs may be associated with increased risk of vision-threatening disease

May 28, 2014
There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to ...

Regular aspirin use ten or more years ago associated with increased risk of type of age-related macular degeneration

December 18, 2012
Among nearly 5,000 study participants, regular aspirin use reported ten years prior was associated with a small but statistically significant increase in the risk of neovascular age‑related macular degeneration, according ...

Genotyping IDs long-term risk of macular degeneration

November 13, 2012
(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing risk when early ...

Impaired autophagy associated with age-related macular degeneration

August 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are caused ...

Findings support link between hsCRP, macular degeneration

February 8, 2013
(HealthDay)—Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein (hsCRP) correlate with increased future risk of age-related macular degeneration (AMD), according to research ...

Patients with AMD may not need monthly injections

May 6, 2014
Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting ...

Recommended for you

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Too little vitamin D may hinder recovery of injured corneas

July 24, 2017
Injury or disease in combination with too little vitamin D can be bad for the window to your eyes.

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.